Community/Retail

An ifosfamide shortage prompts cancer treatment concerns and new importation efforts.

Blood Cancer Awareness Month spotlights types of blood cancer and how pharmacists flag multiple myeloma symptoms early, speeding referral and care.

A prespecified analysis found the PCSK9 inhibitor reduced total events 20% in high-risk patients with no prior heart attack or stroke.

Independent pharmacies should build documentation, watch rule making, and pressing for transparency terms in every contract renewal.

Pediatric and obstetric groups expand high-risk criteria and extend vaccination windows as federal vaccine guidance remains unsettled.

A real-world analysis of matched adults links glucagon-like peptide-1 (GLP-1) receptor agonist use to fewer major cardiovascular events, driven by a mortality benefit.

Both virtual and in-person interviews have their benefits.

Time-to-vaccination data from a large diabetes cohort reveal delayed, incomplete uptake of pneumococcal vaccination, with age and citizenship emerging as the strongest predictors.

Five "essential" outcomes, including medication error and adherence, should anchor every pharmacist intervention study in chronic kidney disease.

A subsequent dispute between state and federal officials over the deaths' classification has thrust the state into the center of a national vaccine policy fight.

A multicohort study finds divergent complication patterns and raises the prospect that millions are being treated for the wrong mechanism.

This FAQ describes what oncology pharmacists should know ahead of Gynecologic Cancer Awareness Month in September.

Pharmacists’ medication expertise can mitigate GI adverse effects and improve outcomes for patients beginning obesity pharmacotherapy

A Medicare GLP-1 bridge program marks 2026, while multiagonists like CagriSema are poised to lead the next wave of obesity therapy.

From statins after 70 to aspirin-free STEMI care, the pharmacist takeaway across 13 trials: identify disease earlier, treat precisely, deliver reliably.

The approval makes ustekinumab the first non-TNF-alpha monoclonal antibody available for both major forms of pediatric inflammatory bowel disease (IBD).

From enlicitide to Lp(a)-lowering siRNAs, a look at the add-on therapies helping high-risk patients reach stricter LDL targets below 55 mg/dL.

Pharmacist Jennifer Goldman on why expectation-setting, GI counseling, and nutrition drive glucagon GLP-1 persistence and long-term success.

IPD survivors face years of sharply elevated recurrence risk, yet vaccination remains low.

Craig Beavers, PharmD, breaks down CARDIO-TTRansform, SINGLE-AF, and POET II—and what each means for anticoagulation, stewardship, and monitoring.

Real-world data show sustained tirzepatide use offset its cost by 12 months in adults older than 55 years, with fewer hospital and ED visits.

Bictegravir/lenacapavir (Bixlenvo) offers the first single-tablet option for many patients with HIV currently receiving complex antiretroviral regimens.

Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.

If Heidi Overton is confirmed, the FDA nominee's views on abortion pills, vaccines, and drug review could reshape pharmacists' daily work.

Andrew Bzowyckyj, PharmD, explains how pharmacists can use albuminuria, ejection fraction, and inflammation to drive earlier CKM risk stratification and patient care.

A diabetologist who lives with type 1 diabetes weighs in on real-time ketone monitoring and what it means for at-risk patients.

Investigators say the nanoparticle candidate's speedy manufacturing process and slow-mutating target could reshape how the field responds to emerging flu strains.

Kidney-protective therapy is now layered. How pharmacists screen, stage by KDIGO, stagger ACE/ARB, SGLT2, GLP-1, and finerenone, and cut CV risk.